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Abstract Objectives: To analyse reports of drug-induced
myocardial infarction and chest pain sent to a national
reporting centre. To review which drugs were suspected
of exhibiting these adverse events and what mechanisms
were involved.
Methods: During the 20-year period 1975 through 1994,
a total of 19 141 reports on adverse reactions to drugs
were received by the Netherlands Centre for Monitoring
of Adverse Reactions to Drugs. Of these 19 141 reports,
220 (1.1%) were concerned with drug-induced chest pain
or myocardial infarction. After excluding reports in
which the causal relationship was unlikely, poorly doc-
umented reports and reports on cases of overdosage, 183
reports (84%) were analysed.
Results: There were 130 reports (71%) of drug-induced
chest pain and 53 reports (29%) of drug-induced myo-
cardial infarction. A total of 104 reports concerned fe-
males (57%). The most frequently reported suspected
drugs were the antimigraine drug sumatriptan (33 re-
ports, 4 concerning myocardial infarction), the calcium
antagonist nifedipin (9 reports, 2 of myocardial infarc-
tion) and nicotine [9 reports (8 patches, 1 chewing gum),
5 concerning myocardial infarction]. There were 18 re-
ports of a fatal outcome.
Conclusions: Several drugs can produce chest pain or
myocardial ischaemia. It is important to recognise drugs
as a potential cause, especially in patients with normal
coronary arteries.
Key words Myocardial infarction, Drug induced, Angi-
na pectoris
Introduction
Research on adverse reactions to drugs is an issue of
growing professional and public interest. Because seri-
ous adverse reactions to drugs are often rare, they are
dicult to detect and investigate. In spite of the low
incidence, it is important to recognise when drugs are the
cause of serious illness. Firstly, if drugs are used for
minor ailments, even a low incidence of a serious adverse
reaction may unfavourably aect the benefit/risk ratio.
Secondly, timely recognition of drugs as the cause of
disease and subsequent discontinuation may be life-
saving. Finally, knowledge on adverse drug reactions
may help to identify groups of patients at particular risk.
The dierent adverse eects of drugs on the heart are
summarised in Table 1. The commonest way in which
drugs adversely aect the function of the heart is by the
production or aggravation of cardiac arrhythmias or
conduction disorders. The next most common adverse
eect of drugs on the heart is the initiation or aggrava-
tion of heart failure. Less frequently, drugs may cause
myocardial ischaemia or infarction or may make the
patient more susceptible to these disorders.
Although voluntary reporting systems have several
disadvantages, especially under-reporting, they have
fundamental value in detecting and characterising rare
adverse drug reactions [1, 2]. In this paper, we present an
analysis of the reports on drug-induced chest pain and
myocardial infarction, received by the Netherlands
Centre for Monitoring of Adverse Reactions to Drugs
(NARD) between 1 January 1975 and 31 December 1994.
Methods
NARD holds a nationwide voluntary reporting scheme for adverse
reactions to drugs. All reports are evaluated by a medical ocer
and discussed at monthly meetings of the advisory board. All
reports received by the NARD between 1 January 1975 and
31 December 1994 concerning drug-induced chest pain, myocardial
ischaemia or infarction were included in this study. Only adverse
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drug reactions due to drugs administered in therapeutic doses were
considered. All reports came from general practitioners, specialist
doctors or hospitals. Minimally requested were data about the age
and sex of the patients, dose and duration of use of the suspected
drug and clinical signs and symptoms. Each report was evaluated
carefully, whereafter the likelihood of a causal relationship was
assessed between use of the suspected drug(s) and the symptoms.
Evaluation of potential causality of the relationship was based on
the temporal relationship of the adverse reaction, pharmacological
potential of the suspected drug(s), exclusion of other possible
causes of myocardial ischaemia, such as coronary stenoses, and the
results of re-exposure (=rechallenge) [3]. A causal relationship was
considered ‘unclassified’ or ‘unlikely’, respectively, when too few
data were available or when more likely causes were found. In the
analysis, reports were excluded if the causal relationship was un-
likely or unclassified.
Acute myocardial infarction was considered to be present if at
least two of the following criteria were present: (1) a recent positive
clinical history of chest pain of at least 30 min; (2) characteristic
changes in the electrocardiogram; and (3) peak elevation of serum
enzymes [creatine phosphokinase (CPK), serum glutamic oxalo-
acetic transaminase (SGOT)] of at least twice the upper limit of
normal.
Dierences between group means were tested by two-tailed
Student’s t-test. A Chi-square statistic was calculated to test dif-
ferences between proportions. Statistical significance was defined as
a P value of less than 0.05.
Results
NARD received, during the study period, a total of
19 141 reports on adverse reactions to drugs. Of these
reports, 220 (1.1%) concerned reports of drug-induced
chest pain or myocardial infarction. Twenty-two reports
(10%) were poorly documented and in 15 reports
(6.8%), the causal relationship was unlikely. The poorly
documented reports and the reports in which the causal
relationship was unlikely were excluded from further
analysis. Three reports, on myocardial infarction to
sumatriptan, nicotine and sulprostons, respectively, have
previously been reported in the literature as a case-re-
port [4].
The 183 reports, which were suitable for analysis,
concerned 103 females (56%) and 80 males (44%), with
an average age of 51 years. There were 130 reports
(71%) of drug-induced chest pain and 53 reports (29%)
of drug induced myocardial infarction. Of the 130 pa-
tients with chest pain attributed to use of drugs, 40 pa-
tients (31%) had a positive rechallenge after renewed
exposure to the drug. Compared with drug-induced
chest pain, drug-induced myocardial infarction was
more frequently reported in males (63 vs 35%;
P < 0.001). Eighteen patients (9.8%) died after myo-
cardial infarction. Age was not related to myocardial
Table 1 Dierent adverse eects of drugs on the heart
Arrhythmias and conduction disorders
Heart failure
Direct: negative inotropism or chronotropism
Indirect: salt and water retention
Myocardial ischaemia/infarction
Direct: reduced coronary blood flow, thrombosis
Indirect: coronary steal, interaction with anti-anginal drugs
Pericardial disease
Haemopericarditis
Others
Table 2 Overview of drugs
which were related to chest pain
or myocardial infarction in 183
reportsa. NSAIDs non-steroidal
anti-inflammatory drugs
Drug group (number of reports) Drug (number of reports)
Cardiovascular (37)
Ca-antagonists (15) Nifedipine (9), diltiazem (4), verapamil (2)
ACE inhibitors (6) Captopril (1), lisinopril (2), perindopril (2), enalapril (1)
b-adrenoceptor blockers (5) Oxprenolol (1), pindolol (1), atenolol (1), metoprolol (2)
a1-adrenoceptor blockers (2) Urapidil (1), prazosin (1)
Other (9) Diuretics (7), ibopamine (1), disopyramide (1)
Central nervous system (53)
Antidepressants (17) Imipramine (1), amitriptyline (2), mianserin (1), moclobemide (4),
fluvoxamine (2), trazodone (2), fluoxetine (3), maprotiline (1),
doxepine (1)
Antipsychotics (1) Clozapine (1)
Anti-migraine (35) Ergotamine (1), sumatriptan (33), methysergide (1)
Respiratory system (15)
b-sympatho-mimetics (7) Salbutamol (3), salmeterol (4), formoterol (2)
Antihistamines (5) Terfenadine (1), cetirizine (2), cinnarizine (2)
Other (3) Theophylline (1), beclomethason (1), noscapine (1)
Hormones (12) Oral contraceptives (4), oestrogens (3),
sulprostone (1), epoetin (1), desmopressin (3)
Anti-infectives (15)
Antibiotics (10) Nitrofurantoin (4), co-trimoxazole (1), amphotericin (1),
amoxicillin (1), metronidazole (1), norfloxacin (1)
Others (6) Mefloquine (3), niridazol (2), ketoconazol (1)
Analgesics (10) NSAIDs (6), glafenine (2), penicillamine (1)
aspirin (1)
Gastro-intestinal drugs (5) Cisapride (2), cimetidine (2), domperidon (1)
Miscellaneous (44) Alfuzosin (3), nicotine (9), amphetamines (2), fenfluramine (2),
b-blocker containing eye drops (4), various (24)
a In nine reports, more than one drug was suspected
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infarction or death. Only in a few patients with drug-
induced chest pain was an ECG performed, but, by the
time this was done, in almost every patient the chest pain
had already disappeared. In six patients abnormal ECGs
were observed.
In 174 out of 183 reports, one drug was suspected to
have caused the adverse reaction, whereas in five reports,
two drugs were suspected and in four reports, more than
two drugs were suspected. Chest pain or myocardial
infarction were attributed to a total of 98 dierent drugs
(Table 2). The drugs most frequently reported were
sumatriptan (33 reports), nicotine (9 reports), nifedipine
(9 reports), diltiazem (4 reports), moclobemide (4 re-
ports) and salmeterol (4 reports).
There were several reports of chest pain or myocardial
infarction attributed to the use of cardiovascular drugs.
Fifteen reports concerned calcium-channel blocking
agents: nine reports concerning nifedipine (seven chest
pain, two acute myocardial infarction), four reports
concerning diltiazem (all chest pain) and two reports
concerning chest pain attributed to use of verapamil.
There were three reports of chest pain induced by sys-
temic use of b-adrenoceptor blockers (oxprenolol, pin-
dolol and atenolol). ACE inhibitors were suspected in
five reports: captopril (one report of chest pain), lisino-
pril (one report of chest pain, one report of myocardial
infarction) and perindopril (one report of chest pain, one
report of myocardial infarction).
There were 17 reports of chest pain or myocardial
infarction attributed to the use of antidepressants. Three
of them concerned fatal myocardial infarction after use
of tricyclic antidepressants (one imipramine, two amitripty-
line). Of four reports concerned with myocardial in-
farction attributed to use of the monoamine oxidase
(MAO)-A inhibitor moclobemide, two concerned a fatal
reaction.
Several reports concerned chest pain or myocardial
infarction attributed to drugs for respiratory problems,
of which seven reports concerning b-sympatho-mimetics
are of special interest.
Four reports concerned adverse reactions attributed
to use of oral contraceptives (two myocardial infarction,
two chest pain), whereas in three reports, chest pain or
myocardial infarction was attributed to other oestro-
gens. One report concerned a myocardial infarction due
to intravenous administration of sulprostone. Three re-
ports concerned chest pain (one report) or myocardial
infarction (two reports) attributed to desmopressin.
Discussion
The most common cause of myocardial ischaemia is
coronary artery sclerosis and stenosis, whereas an acute
myocardial infarction is mostly caused by occlusive
thrombi in atherosclerotic coronary arteries. Transmural
myocardial infarction with angiographically normal
coronary arteries is rare [5] and has been associated with
a defect of fibrinolysis [6], early age [7], cigarette
smoking [8] and drug use. Especially in patients with
chest pain or myocardial infarction and normal coro-
nary arteries, it is important to consider drugs as a po-
tential cause of the complaints.
Although the incidence of acute myocardial infarction
due to drug-induced ischaemia is probably low, there are
several reasons why it is important to know which drugs
can induce myocardial ischaemia and what mechanism is
involved. Firstly, drugs which should be used cautiously
can be identified, especially in patients with coronary
artery disease. Secondly, it is important to consider a
drug adverse event if chest pain occurs in a patient using
some specific drugs, particularly if it is a patient without
any reason to suspect a cardiac origin of the complaints,
for example a young female. Under certain circum-
stances, discontinuation of a specific drug may prevent
myocardial infarction and may be life-saving. Thirdly, in
patients diagnosed as having myocardial infarction or
angina pectoris with normal coronary angiography, the
possibility of an association with the intake of some
drugs should be considered. Fourthly, the diagnostic and
therapeutic approach of patients with drug-induced
myocardial ischaemia or infarction may dier from pa-
tients with regular myocardial ischaemia or infarction.
Finally, the pharmacological mechanisms may also
provide insight into the pathophysiology of ‘not-drug-
induced’ myocardial ischaemia.
It is, of course, important to remember that our re-
ports of chest pain or myocardial infarction concern rare
adverse reactions, and that the risk–benefit assessment
of a specific drug can be only assessed in a (randomised)
clinical trial.
Cardiovascular drugs
There were several reports of chest pain or myocardial
infarction after use of cardiovascular drugs. Especially
interesting were 15 reports of chest pain or myocardial
infarction attributed to calcium-antagonists. Recently,
in a case-control study of hypertensive patients, a rela-
tively higher risk for myocardial infarction was found in
patients taking calcium antagonists [9]. In a meta-anal-
ysis by Furberg et al., a dose-dependent association of
use of nifedipine with mortality was observed [10]. Since
hypertension is associated with both myocardial infarc-
tion and mortality, these associations are explained by
some as a result of confounding by indication [11].
Confounding by indication can even result in a dose-
dependent association. There are, however, several case-
reports in which a relationship between administration
of nifedipine and aggravation of myocardial ischaemia
was observed [12, 13].
There were three reports of chest pain induced by
systemic use of b-adrenoceptor blockers (oxprenolol,
pindolol and atenolol), and four reports of chest pain
induced by b-adrenoceptor blocker-containing eye drops
(timolol 2x, betaxolol, metipranolol). Acute myocardial
infarction has been associated with propranolol [14] and
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metoprolol [15]. Also b-blocker-containing eye drops
have been associated with chest pain [16] and myocardial
infarction [17]. The pathophysiological mechanism of
b-adrenoceptor blocker-induced myocardial ischaemia is
probably coronary vasospasm mediated by a-adreno-
ceptors [15].
A few reports concerned chest pain or myocardial
infarction attributed to the use of ACE inhibitors. In the
literature, several case reports of angina pectoris related
to captopril have been published [18, 19].
Central nervous system
There were three reports of fatal myocardial infarction
attributed to tricyclic antidepressants. This is especially
of interest because, recently, in a case-control study, an
unexpected six fold increase in risk of fatal myocardial
infarction, associated with current use of tricyclic anti-
depressants was demonstrated in young women [20]. In
general, the cardiovascular eects of tricyclic antide-
pressants are considered to consist mainly of conduction
disturbances, arrhythmias and orthostatic hypotension
[21, 22]. Myocardial infarction was attributed to moc-
lobemide in four reports. Recently, hypertension was
described as an adverse reaction to this MAO-A inhib-
itor [23].
Anti-migraine drugs
In the literature, there have been several reports of
cardiac ischaemia due to the antimigraine drugs ergot-
amine [24, 25], methysergide [26], sumatriptan [27] and
isometheptene [28]. The proposed mechanism is coro-
nary spasm. There was a large number of reports sent to
our centre of chest pain (29 reports) and several reports
(four) of myocardial infarction attributed to the use of
the new anti-migraine drug sumatriptan. One report of
myocardial infarction [29] and 13 reports of chest pain
[30] were previously published in the literature as case
reports. In clinical trials, the frequency of chest pain
after use of sumatriptan was approximately 5% [31, 32],
whereas in a postmarketing study, the frequency was
estimated to be 8% [33]. Furthermore, several cardiac
adverse reactions associated with use of sumatriptan
have been reported in the literature [27, 34, 35]. It is,
however, not yet known whether the frequency of car-
diac adverse reactions to sumatriptan is more frequent
than to ergotamine.
Respiratory system
There were six reports of myocardial infarction and one
report of chest pain attributed to use of b-sympatho-
mimetics and one report of myocardial infarction at-
tributed to theophylline. In the literature, acute myo-
cardial infarction following both intravenous and
inhaled treatment with salbutamol has been described
[36, 37]. An increase of mortality in regular users of
b2-adrenoceptor agonists has been demonstrated, but
drug-induced myocardial ischaemia is not considered to
be one of the mechanisms [38]. A case report of a patient
who experienced a myocardial infarction attributed to
use of theophylline was previously published [39]. Fur-
thermore, it has been demonstrated that theophylline
can cause tachycardia and myocardial ischaemia, even at
the recommended doses [40]. However, since cardiac and
respiratory disease commonly co-exist (and have several
risk factors in common, such as smoking) the causal
implications remain dicult to assess.
Hormones
There were two reports of myocardial infarction during
use of oral contraceptives. In fact, this potential asso-
ciation cannot be clarified by case reports, since there is
a lack of clear temporal relationship. In a case-control
study, Thorogood et al. demonstrated that current users
of oral contraceptives had an increased, although not
statistically significant, risk of fatal myocardial infarc-
tion [41]. A more recently published study demonstrated
a reduced risk of myocardial infarction in users of third-
generation oral contraceptives [42].
In two reports of myocardial infarction and in one
report of chest pain, the reactions were attributed to use
of desmopressin. This association has previously been
described in the literature [43].
Analgesics
Coronary spasm has been described after administration
of naproxen (44) and glafenine (45): the proposed
mechanism is an allergic reaction [44].
Miscellaneous
Of the reports of chest pain (n  4) or myocardial in-
farction (n  5) attributed to use of nicotine sent to the
national centre one had previously been published as a
case report [46]. There have been reports of serious
cardiovascular adverse reactions in the literature, in-
cluding acute myocardial infarction and cardiac arrest,
associated with continued smoking during use of the
patches [47–49].
There were two reports of acute myocardial infarc-
tion and one report of chest pain attributed to the use of
alfuzosin. Alfuzosin is a relatively new drug, used for the
symptomatic treatment of benign prostatic hyperplasia,
which acts as an antagonist of a1-adrenoceptors [50].
According to the close temporal relationship with intake
of alfuzosin, the relationship between use of this drug
and the adverse reactions seems to be probable. Al-
fuzosin is, however, often prescribed to patients with a
high risk of coronary diseases (elderly males). There
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were also reports concerning chest pain attributed to two
other a1-adrenoceptor blockers, urapidil and prazosin,
used for treatment of hypertension.
Two reports also concerned chest pain attributed to
use of fenfluramine. Myocardial infarction associated
with dexfenfluramine has been described previously [51].
Underreporting and selective reporting
The most important disadvantages of a spontaneous
reporting system are under-reporting and selective re-
porting. According to the latter, it is particularly inter-
esting that chest pain or myocardial infarction was not
even in one report attributed to cytostatic drugs, blood
coagulation factors or cocaine.
Malignancy may aect the heart by direct invasion,
as in lymphoma or by blood-borne metastases, as in
malignant melanoma [52]. Moreover, several antiprolif-
erative drugs and/or irradiation to the mediastinum can
cause cardiac damage [53–55]. These drugs include 5-
fluorouracil [56], taxol [57], bleomycin and etoposide
[58] and cisplatin [59].
Several cases of myocardial infarction attributed to
the administration of blood coagulation factors have
been documented in the literature [60–62]. In most cases,
patients with haemophilia were involved.
Cases of cocaine-induced myocardial infarction were
previously reviewed in the literature [63].
In conclusion, the present study, the reports of drug-
induced chest pain or myocardial infarction as reported
to the NARD during the period 1975 through 1994 were
demonstrated. The reviewed reports give an impression
of the dierent drugs and the dierent mechanisms in
the dicult field of drug-induced myocardial ischaemia
or infarction.
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